The Hemophilia and Thrombosis Center of Nevada
2020 W. Palomino Lane Suite 110
Las Vegas, Nevada 89106
702-385-2702
since July 3, 2010
Last updated July 3, 2010
webmaster RIS
The Hemophilia and Thrombosis Center of Nevada 2020 W. Palomino Lane Suite 110 Las Vegas, Nevada 89106 702-385-2702
since July 3, 2010 Last updated July 3, 2010 webmaster RIS
|
|
|
ORAL ANTITHROMBIN FOR TREATMENT OF ATRIAL FIBRILLATION Randomized evaluation of long term anticoagulant therapy (RELY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: This study is closed to accrual. The drug has been approved for use in both Europe and Canada. RELY-ABLE is the extension of this study which will allow patients currently assigned to study drug to continue on this medication. This study is also closed to accrual.
The drug is manufactured by Boehringer-Ingelheim. You can learn more about this drug by accessing the web site www.boehringer-ingelheim.com |
|
Send mail to
rshtcn@aol.com with
questions or comments about this web site.
|